Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a year-long campaign to ...

COPENHAGEN, March 2 () - Novo Nordisk said on Monday ‌it will invest 432 million ‌euros ($506.43 million) to expand its ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares rose more than 3% on Wednesday after the U.S. Food and Drug Administration ...

Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result ...

COPENHAGEN, Feb 20 () - Novo Nordisk said on Friday it ‌would nominate Jan van de Winkel ‌and Ramona Sequeira to its board of ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

The Alzheimer’s field is being turned on its head as mounting evidence points to the disease beginning outside the brain many ...

Morgan Stanley upgraded Novo Nordisk to Equal-weight from Underweight, arguing that the recent share price decline has brought valuation more in line with the company’s mid-term risks.

March 5 () - Eli Lilly said on Thursday it had rolled out a platform to ‌help employers connect with organizations offering low-cost ‌benefits and comprehensive obesity-care programs, aiming to widen ...

Novo Nordisk said on Monday its next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, a setback in the race for ...

Investing.com -- Novo Nordisk (CSE:NOVOb) announced Monday it will invest 432 million euros ($506.43 million) to expand its manufacturing facility in Athlone, Ireland.

Novo Nordisk said on Monday (February 23) its next-generation obesity drug CagriSema was less effective than Eli Lilly's ...